Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 13,478 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetic Nephropathy, Nephrotic Syndrome
Interventions: ACTH; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Painful Diabetic Neuropathy
Interventions: Flowaid FA-100 SCCD; Device
Lead sponsor: Rosenblum, Jonathan I., DPM; Individual
Eligibility: 18 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lodi, New Jersey

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 35 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes
Interventions: MEMS caps; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Type 2 Diabetes
Interventions: Diet Beverage, Water; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 35 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Irvine, California • Minneapolis, Minnesota

Conditions: Foot Ulcer, Diabetic
Interventions: PriMatrix; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20), Liquid meal; Drug · Other
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Diabetes Mellitus
Interventions: Community-Clinical Intervention; Behavioral
Lead sponsor: Mary Lacy; Other
Eligibility: 18 Years and older
Enrollment: 12,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cancer
Interventions: polymorphism analysis, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin, Sitagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 79
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more

Conditions: Type 1 Diabetes
Interventions: Acetazolamide; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Thyroid Cancer
Interventions: sorafenib with everolimus; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Interventions: miRNAseq analysis, Standard treatment for bone disorder; Procedure · Drug
Lead sponsor: Thomas Nickolas; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2 Diabetes, Obesity
Interventions: WW Intervention, Usual Care; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Stanford, California • Baton Rouge, Louisiana • Winston-Salem, North Carolina

Conditions: Congenital Hyperinsulinism, Insulinoma
Interventions: Fluorodopa F 18; Drug
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: Up to 18 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Diabetes Mellitus, Type 2, Diabetes Mel Gestational - in Pregnancy
Interventions: Nutrition-behavior lifestyle program; Behavioral
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: semi-structured interviews; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Interventions: zenocutuzumab (MCLA-128); Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 26
States / cities: Phoenix, Arizona • Cerritos, California • Irvine, California + 21 more

Conditions: Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Interventions: Standard of Care, BIOxHEAL (human amniotic membrane allograft); Other · Biological
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Self-Affirmation; Behavioral
Lead sponsor: Elizabeth Scharnetzki; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Westbrook, Maine

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: PF-04991532, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more

Conditions: Ovarian Cancer
Interventions: Interview, Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

An Evaluation of an SCCD on the Symptomatology of Painful DPN

Nutritional Therapy for Diabetic Cardiomyopathy

Diabetes and Gastric By- Pass

Improving Compliance With Metformin

Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes

The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Leveraging Community-clinical Linkages to Address Unmet Social Needs for People With Diabetes

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

Acetazolamide in Persons With Type 1 Diabetes - Dose Finding

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

Precision Medicine Approaches to Renal Osteodystrophy

Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Community-Based Nutrition-Lifestyle Therapy for Pregnant Latina Women With Diabetes

Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

Strategies to Improve Well-Being and Diabetes Management

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

Chemotherapy-Related Toxicities In Ovarian Cancer Patients